$180,000 of HARMONY BIOSCIENCES lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act"
You can find more data on corporate lobbying on Quiver Quantitative.
HRMY Insider Trading Activity
HRMY insiders have traded $HRMY stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $HRMY stock by insiders over the last 6 months:
- SANDIP KAPADIA (CHIEF FINANCIAL OFFICER) sold 21,573 shares for an estimated $787,377
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HRMY Hedge Fund Activity
We have seen 157 institutional investors add shares of HRMY stock to their portfolio, and 103 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 862,406 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $27,252,029
- FMR LLC removed 654,333 shares (-12.2%) from their portfolio in Q2 2025, for an estimated $20,676,922
- BOSTON PARTNERS added 605,495 shares (+inf%) to their portfolio in Q2 2025, for an estimated $19,133,642
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 508,498 shares (+127.6%) to their portfolio in Q2 2025, for an estimated $16,068,536
- NEW VERNON CAPITAL HOLDINGS II LLC removed 473,708 shares (-97.0%) from their portfolio in Q2 2025, for an estimated $14,969,172
- NORGES BANK removed 457,287 shares (-97.6%) from their portfolio in Q2 2025, for an estimated $14,450,269
- VANGUARD GROUP INC added 411,427 shares (+8.8%) to their portfolio in Q2 2025, for an estimated $13,001,093
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HRMY Analyst Ratings
Wall Street analysts have issued reports on $HRMY in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Deutsche Bank issued a "Buy" rating on 09/25/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/25/2025
- Mizuho issued a "Outperform" rating on 09/25/2025
- Oppenheimer issued a "Outperform" rating on 06/02/2025
- Needham issued a "Buy" rating on 05/07/2025
- UBS issued a "Buy" rating on 04/28/2025
To track analyst ratings and price targets for HRMY, check out Quiver Quantitative's $HRMY forecast page.
HRMY Price Targets
Multiple analysts have issued price targets for $HRMY recently. We have seen 7 analysts offer price targets for $HRMY in the last 6 months, with a median target of $43.0.
Here are some recent targets:
- Ashwani Verma from UBS set a target price of $43.0 on 10/15/2025
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $55.0 on 09/25/2025
- Graig Suvannavejh from Mizuho set a target price of $35.0 on 09/25/2025
- David Hoang from Deutsche Bank set a target price of $36.0 on 09/25/2025
- Ami Fadia from Needham set a target price of $41.0 on 09/24/2025
- Danielle Brill from Truist Securities set a target price of $48.0 on 07/21/2025
- Andreas Argyrides from Oppenheimer set a target price of $61.0 on 06/02/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
